Pyrazole trk kinase inhibitors for the treatment of cancer

Abstract

Two related applications from AstraZeneca claim novel pyrazole derivatives and their process for preparation as trk kinase inhibitors for use in oncology. The compounds are claimed for stand-alone or combination therapy. The two series, which differ by position of attachment of the pyrazole group, are prepared from a common intermediate by reversing the order of the aminopyrazole step. TrkA kinase data are provided for three examples in each application.

Keywords::

• NGF
• pyrazole
• trkA

Patent Details

• Title Chemical compounds

• Assignee AstraZeneca

• Inventors Han Y, Lamb M, Mohr P, Yu D, Wang B, Wang T,

• Priority date 16/02/2005 & 03/11/2005

• Filing date 15/02/2006

• Publication date 24/08/2006

• Publication no. WO2006/087538

• Title Chemical compounds

• Assignee AstraZeneca

• Inventors Lamb M, Mohr P, Wang B, Wang T, Yu D

• Priority date 16/02/2005 & 01/12/2005

• Filing date 15/02/2006

• Publication date 24/08/2006

• Publication no. WO2006/087530

Notes